In this episode of Meeting Mic, Oncology Overdrive host, Shikha Jain, MD, is joined by Akriti Jain, MD, to discuss innovations in the management of acute myeloid leukemia, as well as highlights and abstracts from ASCO Annual Meeting.

· What advances have you seen in AML care over the past 10 to 12 years? 5:57

· How do you manage treatment of patients with TP53-mutated AML? 13:39

· What types of disparities do you see in your patient populations? 15:48

· What advice do you give patients to help them better understand the benefits of clinical trials? 20:51

· What abstracts were you most excited about at ASCO this year? 25:18

· Is personalized care becoming more of a focus in AML management? 27:19

We'd love to hear from you! For more from Dr. Shikha Jain, follow her on X: @ShikhaJainMD and on Instagram: @shikhajainmd. For more from Dr. Akriti Jain, email jaina9@ccf.org.

Shikha Jain reports no relevant financial disclosures. Akriti Jain reports advising/consulting roles with Ascentage Pharma, Daiichi Sankyo, Novartis, Servier, Sobi, Syndax and Takeda, and research funding from Novartis and Servier. She also has served as a speaker for Geron, PharmaEssentia and Rigel Pharmaceuticals.

References:

· Granat LM, et al. Abstract 6587. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

· Pino-Ascencio S, et al. Abstract 6580. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.